MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Home・Aandelen Lijst・Champions Oncology Inc

C
Champions Oncology Inc

Gesloten

SectorGezondheidszorg

6.69 3.4

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

6.47

Max

6.72

Belangrijke statistieken
By Trading Economics
Inkomsten	702K 236K
Verkoop	1M 15M
K/W Sectorgemiddelde	40.588 88.032
Winstmarge	1.57
Werknemers	213
EBITDA	1.1M 612K

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+73.66% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-12M 96M
Vorige openingsprijs	3.29
Vorige sluitingsprijs	6.69

Nieuwssentiment

By Acuity

35%

65%

112 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

5.77 / 7.61 Steun & Weerstand

Champions Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 dec 2025, 22:20 UTC

Belangrijke Marktbewegers

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 dec 2025, 17:31 UTC

Belangrijke Marktbewegers

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 dec 2025, 16:30 UTC

Belangrijke Marktbewegers

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 dec 2025, 15:19 UTC

Belangrijke Marktbewegers

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 dec 2025, 15:17 UTC

Belangrijke Marktbewegers

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 dec 2025, 14:37 UTC

Belangrijke Marktbewegers

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

31 dec 2025, 21:13 UTC

Acquisities, Fusies, Overnames

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 dec 2025, 20:40 UTC

Marktinformatie

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 dec 2025, 20:22 UTC

Marktinformatie

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 dec 2025, 19:50 UTC

Marktinformatie

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 dec 2025, 19:31 UTC

Marktinformatie

Precious Metals Cap Off Record Runs -- Market Talk

31 dec 2025, 18:50 UTC

Marktinformatie

Global Equities Roundup: Market Talk

31 dec 2025, 18:50 UTC

Marktinformatie

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 dec 2025, 17:17 UTC

Marktinformatie

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 dec 2025, 17:16 UTC

Belangrijke Marktbewegers

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

31 dec 2025, 17:00 UTC

Acquisities, Fusies, Overnames

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 dec 2025, 15:57 UTC

Acquisities, Fusies, Overnames

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 dec 2025, 15:54 UTC

Marktinformatie

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 dec 2025, 15:02 UTC

Belangrijke Marktbewegers

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 dec 2025, 14:40 UTC

Acquisities, Fusies, Overnames

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 dec 2025, 14:20 UTC

Marktinformatie

Crude Futures On Track to End the Year With Losses -- Market Talk

31 dec 2025, 13:46 UTC

Marktinformatie

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31 dec 2025, 13:01 UTC

Winsten

Acquisities, Fusies, Overnames

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31 dec 2025, 11:10 UTC

Marktinformatie

Copper Remains in Touching Distance of Record Highs -- Market Talk

31 dec 2025, 10:46 UTC

Marktinformatie

Euro on Track For Strong Annual Performance -- Market Talk

31 dec 2025, 10:25 UTC

Marktinformatie

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31 dec 2025, 10:23 UTC

Marktinformatie

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31 dec 2025, 09:33 UTC

Marktinformatie

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Peer Vergelijking

Prijswijziging

Champions Oncology Inc Prognose

Koersdoel

By TipRanks

73.66% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 12 USD 73.66%

Hoogste 12 USD

Laagste 12 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Champions Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Champions Oncology Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.77 / 7.61Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

112 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Champions Oncology Inc

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.